PPARG and lung adenocarcinoma: In lung adenocarcinoma cells treated with transforming growth factor β (TGF-β), a potent EMT inducer [42], PPARγ activation counteracts the loss of E-cadherin expression and inhibits the induction of mesenchymal markers, thus preventing migration and invasion [43].